Tekton Research Scales Clinical Trial Network with Strategic Site Additions and Expert Leadership

Tekton Research, a leading multi-site clinical trial company, is proud to announce the addition of three new sites, five new Principal Investigators (PIs...

September 29, 2025 | Monday | News
Trump Prescribes a 100% Tariff: Because Nothing Says “Affordable Healthcare” Like Doubling the Price of Pills

US President Donald Trump has announced a 100% import tariff on all branded or patented pharmaceutical products, effective 1 October. The steep duty will d...

September 28, 2025 | Sunday | Analysis
Actio Biosciences Doses First Participant in Phase 1a Trial of ABS-1230 for KCNT1-Related Epilepsy

Actio Biosciences, a clinical-stage biotechnology company leveraging a novel approach to genetics and precision medicine to develop new small molecule th...

September 24, 2025 | Wednesday | News
Remedium Bio and Eli Lilly Enter Multi-Target Gene Therapy Collaboration in Type 2 Diabetes and Obesity

Lifespan Vision Ventures is pleased to announce that its portfolio company, Remedium Bio, Inc. ("Remedium"), has entered into a multi-target research and...

September 24, 2025 | Wednesday | News
Illumina Expands Global CDx Partnerships to Advance KRAS-Targeted Precision Oncology

Illumina Inc. (NASDAQ: ILMN) will partner with multiple global pharmaceutical companies to develop companion diagnostics (CDx) enabled on the T...

September 24, 2025 | Wednesday | News
Rise Therapeutics Expands Oral Dendritic Cell Modulator Program into Sjögren’s Disease Following Positive RA Clinical Data

Supported by recent clinical data from the first-ever clinical study of an oral dendritic cell (DC) modulator in rheumatoid arthritis (RA), Rise Therapeu...

September 24, 2025 | Wednesday | News
Revvity and Profluent Join Forces to Advance AI-Enhanced Base Editing with Pin-point™ Platform

Combination of Revvity’s proprietary Pin-point platform and Profluent’s AI-engineered proteins created to inspire accelerated development o...

September 23, 2025 | Tuesday | News
Australia’s Immutep and GW Cancer Center Launch Phase II Trial of Efti in Early-Stage HR+/HER2-Negative Breast Cancer

GW Cancer Center to initiate Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy prior to surgery in HR+/HER...

September 23, 2025 | Tuesday | News
Pfizer Tucks Into $4.9 Billion Metsera Feast — Because Nothing Says Slimming Like Bulking Up

  Proposed acquisition to add four highly differentiated clinical-stage incretin and amylin programs to Pfizer’s pipeline Transaction valu...

September 23, 2025 | Tuesday | News
Kensana Health Partners With GEM Global Yield on $120 Million Facility to Advance AI-Driven Plant-Based Medicines

Kensana Health Inc. announced it has entered into a share subscription facility of up to $120 million with GEM Global Yield LLC SCS ("GEM"), a Luxembourg...

September 22, 2025 | Monday | News
Greenwich LifeSciences Expands Phase III FLAMINGO-01 Breast Cancer Trial to Ireland

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO...

September 19, 2025 | Friday | News
Crown Bioscience Expands US Footprint with New State-of-the-Art Model Development Center in Kannapolis, North Carolina

Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corp...

September 18, 2025 | Thursday | News
VintaBio Files Patents for Breakthrough Biotherapeutics Manufacturing Platform That Slashes Development Timelines

Proprietary process reduces development timelines from 18 months to as little as 3, eliminates reliance on traditional plastic flatware, and offers rap...

September 17, 2025 | Wednesday | News
Allot and SnapLogic Launch AI Agent to Tackle Health Inequalities Using Advanced Data Integration

New AI agent turns complex healthcare and environmental data into actionable insights for pharmaceutical teams. SnapLogic, the Agentic Integra...

September 17, 2025 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close